Sign in
Taking people in United StatesPhase 2

Acetazolamide in Central Sleep Apnea Patients Using Medication for Opioid Use Disorder

Key facts

Who runs it
Sanjay R Patel
Where
Pittsburgh, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
40 people, planned
Started
30 Sept 2025
Expected to end
Feb 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Acetazolamide
  • Placebo
Record updated
25 June 2026

Who can take part

Age
18 years to 100 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Patients on Medication for Opioid Use Disorder (MOUD) with central sleep apnea

Who cannot take part

  • Sleep-related Hypoventilation
  • Other causes of Central Sleep Apnea besides Opioid Use
  • Pregnancy
  • Contraindications for Acetazolamide

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 100 years old?

Where in United States

  • University of PittsburghPittsburgh, United StatesContact: Madeline GudobbaTaking people

About the trial

What the trial wants to find out

Patients with opioid use disorder treated with either methadone or buprenorphine are at risk of developing central sleep apnea (CSA) from these medications. Investigators will conduct a mechanistic trial using acetazolamide, a medicine known to improve CSA in other settings, to determine if acetazolamide can improve CSA due to medication for opioid use disorder and whether this leads to physiologic changes that might lead to reduced drug craving. Patients treated with medication for opioid use disorder and who have central sleep apnea will be randomized to treatment with acetazolamide or matching placebo for 7 days. At the end of the 7 days, they will undergo an overnight sleep study to assess the impact on breathing during sleep as well as sleep quality. In addition, measures of sympathetic tone, anxiety, arousal, cognition, and drug craving will be measured to determine if treatment of CSA with acetazolamide can produce physiologic changes that might contribute to improved health.

The 2 groups in the trial

  • AcetazolamideTreatment being tested

    All participants in this group will receive one acetazolamide 250 mg pill in the evening for 7 days.

  • PlaceboPlacebo, for comparison

    All participants in this group will receive one matching placebo pill in the evening for 7 days.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Impact of Acetazolamide on Central Sleep Apnea Patients Receiving Medication for Opioid Use Disorder
Criteria questions
Built from NCT06521476, who can take part
Record updated
25 June 2026